13 Participants Needed

huCART-meso + VCN-01 for Pancreatic Cancer

JL
AC
Overseen ByAbramson Cancer Center Clinical Trials Services
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: University of Pennsylvania
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on high-dose corticosteroids or certain immunotherapy drugs, you may need to stop or adjust them before participating.

What data supports the effectiveness of the huCART-meso + VCN-01 treatment for pancreatic cancer?

Research shows that T cells engineered with chimeric antigen receptors (CAR T cells) can target and kill cancer cells in pancreatic cancer models, particularly those expressing mesothelin, a protein often found in these tumors. These CAR T cells have been effective in reducing tumor growth and eliminating metastases in animal studies, suggesting potential for treating pancreatic cancer in humans.12345

Is the huCART-meso + VCN-01 treatment safe for humans?

The research on CAR T cell therapy, which includes huCART-meso, suggests it can be effective against pancreatic cancer cells, but there are concerns about safety, particularly 'on-target, off-tumor' toxicity, which means the treatment might affect healthy cells as well. The studies focus on improving safety by using different methods to engineer the cells, but specific safety data for humans is not detailed in the available research.12567

What makes the huCART-meso + VCN-01 treatment unique for pancreatic cancer?

The huCART-meso + VCN-01 treatment is unique because it combines genetically modified immune cells (huCART-meso) with an oncolytic virus (VCN-01) to target pancreatic cancer, offering a novel approach compared to traditional chemotherapy. This combination aims to enhance the immune system's ability to recognize and destroy cancer cells while the virus selectively infects and kills tumor cells.3891011

What is the purpose of this trial?

This trial is testing a combination of modified immune cells and a virus-based therapy in patients who may not have responded to other treatments. The immune cells are designed to target and destroy cancer cells, while the virus helps by killing cancer cells and enhancing the immune response. The virus therapy has been approved for the treatment of metastatic melanoma.

Research Team

JL

Janos Tanyi, MD, PhD

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for adults with specific advanced cancers: unresectable or metastatic pancreatic adenocarcinoma, and persistent or recurrent serous epithelial ovarian cancer. Participants must have tried at least one standard chemotherapy, be in good physical condition (ECOG 0-1), not need oxygen therapy, and have no other active invasive cancers or significant health issues like heart disease, autoimmune diseases requiring steroids, or certain infections.

Inclusion Criteria

Subjects providing written informed consent
My organs and bone marrow are functioning well.
My pancreatic cancer cannot be removed by surgery and has spread.
See 7 more

Exclusion Criteria

Pregnant or breastfeeding women
I do not have serious heart fluid buildup or heart conditions that could affect the study.
I have chronic hepatitis C with moderate to severe liver scarring.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VCN-01 and huCART-meso cells in a 3+3 dose escalation design. Cohort 1 receives VCN-01 on Day 0 and huCART-meso on Day 14. Cohort 2 receives a higher dose of VCN-01 on Day 0 and huCART-meso on Day 14. Cohort -1, if needed, receives huCART-meso on Day 0 and VCN-01 on Day 10.

14 days per cohort

Follow-up

Participants are monitored for safety and effectiveness after treatment, with formal DLT assessments performed by the Clinical PI and Sponsor Medical Director.

6 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term if the dose combination is identified as the recommended phase 2 dose (RP2D).

Treatment Details

Interventions

  • huCART-meso Cells
  • VCN-01
Trial Overview The study tests a combination of huCART-meso cells and VCN-01 on patients with ovarian and pancreatic cancer using a '3+3 dose escalation' method to find the safest dose. This means small groups of patients receive increasing doses until doctors determine the highest dose that can be given safely.
Participant Groups
3Treatment groups
Active Control
Group I: Cohort 2Active Control2 Interventions
Single dose of 1x10(13) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.
Group II: Cohort -1Active Control2 Interventions
In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Enrolled subjects will receive a single dose of huCART-meso cells on Day 0 followed by a single dose of 3.3x10(12) vp of VCN-01 on Day 14.
Group III: Cohort 1Active Control2 Interventions
Single dose of 3.3x10(12) vp of VCN-01 on Day 0, followed by a single dose of 5x10(7) of huCART-meso cells on Day 14.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pennsylvania

Lead Sponsor

Trials
2,118
Recruited
45,270,000+

Theriva Biologics

Collaborator

Trials
1
Recruited
10+

Theriva Biologics SL

Industry Sponsor

Trials
5
Recruited
180+

VCN Biosciences, S.L.

Industry Sponsor

Trials
5
Recruited
180+

Findings from Research

Meso-CART cells, engineered T cells targeting mesothelin, showed promising anti-tumor effects against pancreatic cancer, particularly in eliminating lung metastases in mice, indicating potential for treating advanced stages of the disease.
This study is the first to demonstrate that meso-CART cells can effectively target and reduce distant metastases, suggesting they could be a viable immunotherapy option for patients with mesothelin-positive pancreatic tumors.
Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer.Sun, Q., Zhou, S., Zhao, J., et al.[2019]
The study developed dual-receptor CAR-modified T cells (dCAR-T) that effectively target pancreatic cancer cells expressing both carcino-embryonic antigen (CEA) and mesothelin (MSLN), demonstrating high anti-tumor activity in vitro and in vivo.
dCAR-T cells showed significant cytotoxicity against tumor cells with both antigens while sparing those with only one, reducing the risk of 'on-target, off-tumor' toxicity and allowing for more precise CAR-T cell therapy.
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.Zhang, E., Yang, P., Gu, J., et al.[2021]
A new method successfully cultured primary pancreatic cancer cell lines (PPCLs) from patient-derived xenografts, achieving a 100% success rate in expanding these cells, which helps preserve the tumor's original characteristics.
The PPCLs maintained intratumoral heterogeneity and expressed key cancer and immune markers, making them a valuable tool for personalized therapy research and better understanding of pancreatic cancer biology.
Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.Pham, K., Delitto, D., Knowlton, AE., et al.[2018]

References

Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer. [2019]
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. [2021]
Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. [2018]
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. [2023]
The Potential of CAR T Cell Therapy in Pancreatic Cancer. [2022]
Generation of Induced Pluripotent Stem Cell-Like Lines from Human Pancreatic Ductal Adenocarcinoma. [2019]
Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. [2021]
Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. [2023]
Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. [2022]
Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security